THE EXPRESSION OF PROGRAMMED DEATH-LIGAND 1 (PD-L1) IN NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS WITH STAGE IV AT HANOI MEDICAL UNIVERSITY HOSPITAL
Main Article Content
Abstract
Objective: Analysis the correlation of the expression of PD-L1 with characteristics of NSCLC patients with stage IV at Hanoi Medical University Hospital. Patients and methods: Descriptive study on 32 NSCLC patients with stage IV who had PD-L1 test at Medical University Hospital from June 2021 to June 2022. Results: The negative rate of PD-L1 expression was 53.1%, 25.0% of the cases had intermediate (1-49%), and the rate of high positive (≥ 50%) was 21.9%. The rate of positive PD-L1 expression was higher in the group of ≥50 years old, female (55.6%) was higher than male (43.5%), the smokers (56.2%) was higher than the non-smoker (37.5%), the sampling site of the primary lung tumor (47.1%) was higher than the cell block of pleural fluid or distant organ metastasis, although there were no statistically significant differences with p>0.05. There was no relationship between PD-L1 expression rate and specimen collection method, number of metastatic organs, EGFR mutation, or NLR ratio. Conclusions: The NSCLC patients with stage IV have a relatively high rate of PD-L1 positivity, even in the absence of EGFR gene mutations.
Article Details
Keywords
Non small cell lung cancer, PD-L1
References
2. Cancer of the Lung and Bronchus - Cancer Stat Facts. SEER. Accessed May 24, 2021. https://seer.cancer.gov/statfacts/html/lungb.html
3. Brahmer JR, Govindan R, Anders RA, et al. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC). J Immunother Cancer. 2018;6(1):75. doi:10.1186/s40425-018-0382-2
4. Trần Thị Tươi. Xác định sự bộc lộ của PD-L1 trên bệnh nhân ung thư phổi không tế bào nhỏ tại bệnh viện K. Published online 2018.
5. Aggarwal C, Abreu DR, Felip E, et al. Prevalence of PD-L1 expression in patients with non-small cell lung cancer screened for enrollment in KEYNOTE-001, -010, and -024. Ann Oncol. 2016;27:vi363. doi:10.1093/annonc/mdw378.14
6. Rizvi H, Bandlamudi C, Schoenfeld AJ, et al. Molecular correlates of PD-L1 expression in patients with non-small cell lung cancer. J Clin Oncol. 2019; 37(15_suppl):9018-9018. doi:10.1200/ JCO.2019.37.15_suppl.9018
7. Dietel M, Savelov N, Salanova R, et al. Real-world prevalence of programmed death ligand 1 expression in locally advanced or metastatic non-small-cell lung cancer: The global, multicenter EXPRESS study. Lung Cancer Amst Neth. 2019;134:174-179. doi:10.1016/j.lungcan.2019.06.012
8. Hasegawa T, Yanagitani N, Utsumi H, et al. Association of High Neutrophil-to-Lymphocyte Ratio With Poor Outcomes of Pembrolizumab Therapy in High-PD-L1-expressing Non-small Cell Lung Cancer. Anticancer Res. 2019;39(12):6851-6857. doi:10.21873/anticanres.13902